Sartorius Stedim Biotech Acquires U.S.-Based Purification Expert WaterSep BioSeparations LLC

Sartorius Stedim Biotech | December 10, 2020

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical business, today procured U.S.- based filtration master WaterSep BioSeparations LLC. WaterSep BioSeparations develops, makes and markets empty fiber layer gadgets and pre-cleaned congregations for upstream and downstream biopharmaceutical applications. The exclusive organization situated in Marlborough, Massachusetts, USA, employs around 15 individuals and is required to procure income of approximately 2.5 million U.S. dollars in 2020 at solid development rates and a generous twofold digit EBITDA edge. The gatherings conceded to a price tag of roughly 27 million U.S. dollars in addition to a procure out segment of up to 9 million U.S. dollars, contingent upon the accomplishment of characterized deals revenue growth by 2023.

This official statement contains forward-looking articulations about the future development of the Sartorius Stedim Biotech Group. Forward-looking proclamations are liable to known and obscure dangers, vulnerabilities and different elements that could make real outcomes vary substantially from those communicated or suggested by such explanations. Sartorius Stedim Biotech accepts no risk for refreshing such articulations considering new data or future occasions. This is an interpretation of the first French-language public statement. Sartorius Stedim Biotech will not assume any risk for the accuracy of this translation. The first French official statement is the legally binding version.


The human cell atlas is an international, collaborative effort that aims to define all human cell types, in terms of their distinctive patterns of gene expression, physiological states, location, and developmental trajectories. The immune cell atlas is part of the select group of atlases that will contribute to the ‘first draft’.


The human cell atlas is an international, collaborative effort that aims to define all human cell types, in terms of their distinctive patterns of gene expression, physiological states, location, and developmental trajectories. The immune cell atlas is part of the select group of atlases that will contribute to the ‘first draft’.

Related News


Labcorp and PathAI Expand their Partnership to Accelerate Use of AI-Powered Pathology

PathAI, Labcorp | March 09, 2021

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Development. A critical focal point of the extended joint effort will be to empower, in planned clinical trials of cancer and different diseases, the seamless deployment of PathAI's algorithms in the expansive arrangement of projects oversaw by Labcorp Drug Development. These PathAI algorithms are created utilizing Good Clinical Laboratory Practice (GCLP) rules and cycle controls and are bolted and validated as fit for reason; they can likewise be additionally reached out to companion diagnostic (CDx) gadget development and commercialization. They can be sent in review or imminent clinical trials to evaluate tissue-based biomarkers and can uphold patient stratification and selection. The algorithms have numerous potential extra uses where robust deployment and information assortment are required. Labcorp and PathAI plan to investigate connecting the utilization of AI-powered algorithms from translational research into a clinical laboratory setting. “We are very impressed with the vision that Labcorp has for the future of AI-powered pathology in drug development and diagnostics, and we look forward to joining forces to enable our bio-pharma partners to obtain the most accurate, standardized, and data-rich set of pathology readouts from clinical trials to help advance drug development,” said PathAI CEO Andy Beck. “After exploring successful initial projects with Labcorp, we are excited to leverage the scale of its network to grow the reach of digital and computational pathology with the goal of ultimately improving patient outcomes.” “It has been great working with PathAI to expand computational pathology applications in oncology and other diseases that have often been resistant to digitization,” said Paul Kirchgraber, M.D., CEO, Labcorp Drug Development. “This collaboration will provide our bio-pharma partners a differentiated understanding of relevant patient characteristics through applying leading AI-driven algorithms to support clinical trials from novel biomarker development through patient stratification and companion diagnostic development.” About PathAI PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. About Labcorp Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp reported revenue of $14 billion in FY2020.

Read More


Vibe Bio Announced the Launch to Develop Novel Treatments for Rare Diseases

Vibe Bio | June 23, 2022

Vibe Biotechnology Inc., a biotechnology company committed to identifying, funding, and developing promising treatments for rare diseases, announced officially launching with $12 million in funding to advance its community-driven approach to transforming drug development for patients with rare diseases. Vibe Bio plans on building a global community of scientists, researchers, patients, and partners with an aim to find cures for rare diseases by efficiently using a decentralized autonomous organization (DAO), The company’s DAO will serve as an online coordination hub for its numerous stakeholders, connecting patients directly to researchers, scientists, investors, and other experts. In addition, through its $VIBE governance token, members of Vibe Bio can vote and nominate which specific diseases, candidate medicines, or rare disease research proposals to pursue. These proposals will each be vetted by financial experts and scientists. Vibe Bio has already joined hands with two patient advocacy organizations to launch and fund independent biotechnology companies for developing and pursuing effective therapeutic solutions for rare and often fatal diseases. One in 10 Americans is living with a rare disease. For too many, the time it would take to develop a cure is longer than the time they have left to live, The challenge for rare diseases isn’t necessarily finding a treatment – it’s funding it. For the first time, Vibe Bio is giving patients with rare and overlooked diseases access to the funding and community support they need to develop cures and ownership over the results.” Alok Tayi, Ph.D., co-founder and CEO of Vibe Bio. Vibe Bio is building a new approach to drug development that is providing a lifeline – and renewed hope – for patients and their families, I’m thrilled to be a part of its community and champion its mission as Vibe Bio identifies and funds medicines that will improve the quality of life for people living with rare diseases.” Parul Singh, Partner at Initialized Capital.

Read More


MacroGenics Uses Genedata Profiler to Improve Immunotherapy Development

MacroGenics, Genedata | April 20, 2021

Genedata, the leading supplier of enterprise software solutions for biopharmaceutical R&D, revealed today a long-term collaboration agreement with MacroGenics, a biopharmaceutical firm and emerging pioneer in discovering and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics access to Genedata Profiler® as well as consulting services to aid in the platform's accelerated adoption and integration into MacroGenics' R&D infrastructure. The use of Genedata Profiler improves MacroGenics' ability to generate new hypotheses from combined databases from both proprietary and public sources, assisting in the interpretation of biomarker data and the design of clinical trials. The Genedata Profiler software provides MacroGenics with a comprehensive solution that solves a variety of problems while also presenting new possibilities, such as: • Aggregation and curation of dispersed clinical and non-clinical research data, in a central repository, to create an institutional memory; • Self-service access to data and easy-to-use analytical tools empowers data scientists and clinicians to run complex analyses in a controlled and secure environment; • Cross-study and cross-technology data integration and analysis unlock actionable insights and facilitate informed decision-making; and • Automated workflows for data harmonization, integration, and analytics streamlines and standardizes analytical processes, while ensuring data reproducibility. MacroGenics profits from Genedata's technical domain experience in data analytics and interpretation, IT support, and scientific consulting in addition to software while retaining sole ownership of its proprietary data. The MacroGenics science team is collaborating closely with Genedata experts to unlock the potential of their data and advance their translational and clinical research programs. MacroGenics will be able to produce new scientific insights and hypotheses due to the streamlined, data-driven approach provided by Genedata Profiler. • Accelerate the discovery and development of predictive biomarkers indicative of therapy response to define the best subpopulation of patients to benefit from their immunotherapies, • Identify drugs’ specific indications to improve clinical trials inclusion criteria, • Determine the therapeutic mechanism of action (pharmacodynamics) to strengthen the rationale of the treatment regimen. Genedata Profiler, which is already in operation, has advanced MacroGenics' internal data organization and formatting. Data integration workflows and applied analytics conducted within the system have enhanced many existing translational/clinical trials and resulted in findings for presentations at international conferences (ASCO, ASH). MacroGenics will continue to work with Genedata to improve their analytical capability to help forward and reverse translational studies. About Genedata Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.

Read More